Can I Take Omega-3 (EPA/DHA) with Vyleesi (Bremelanotide)?

What is bremelanotide (Vyleesi), and how does it differ from other HSDD drugs?

Bremelanotide, brand name Vyleesi, is a melanocortin receptor agonist approved by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is given as a 1.75 mg subcutaneous injection roughly 45 minutes before anticipated sexual activity, limited to one dose in 24 hours. It works centrally, at MC1R, MC3R, and MC4R receptors, and is distinct from flibanserin (Addyi), an oral daily serotonergic agent also approved for HSDD. This article addresses only bremelanotide, not flibanserin.

According to the FDA prescribing information, bremelanotide is metabolized primarily by hydrolysis of amide bonds rather than by hepatic cytochrome P450 (CYP) enzymes, and it is eliminated through a combination of renal and fecal routes. The label states that bremelanotide does not meaningfully inhibit or induce the major CYP enzymes at clinically relevant concentrations. This non-CYP metabolism matters for the omega-3 question: standard-dose fish oil supplements are not significant CYP inhibitors or inducers either, so the two do not compete for the same clearance pathway. according to FDA prescribing information for Vyleesi

The label also carries a warning about transient blood pressure increases after injection and a contraindication for women with uncontrolled hypertension or known cardiovascular disease. It separately notes that bremelanotide can slow gastric emptying, which is relevant to orally administered drugs that depend on rapid absorption, but this does not apply meaningfully to fish oil capsules.

What are omega-3 fatty acids (EPA/DHA), and where do they fit pharmacologically?

Omega-3 polyunsaturated fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are marine or algal-derived fatty acids sold both as over-the-counter supplements (typically 300 mg to 1,200 mg combined EPA/DHA per capsule) and as FDA-approved prescription products at 4 g/day for triglyceride reduction or cardiovascular risk reduction in specific high-risk populations. as noted in FDA drug approval announcements for omega-3 products

Two mechanisms are relevant to this interaction question:

Platelet function. EPA and DHA compete with arachidonic acid for cyclooxygenase binding, which reduces thromboxane A2 production and modestly inhibits platelet aggregation. This effect is dose-dependent and is generally described in the literature as becoming more consistently measurable at higher intakes (roughly 3 g/day and above) rather than at typical 1 g/day supplement doses. The exact dose-response threshold varies across studies and should be treated as approximate rather than a fixed clinical cutoff.

Blood pressure. Fish oil supplementation has a modest antihypertensive effect in several trials, generally on the order of a few mmHg reduction in systolic pressure among people with elevated baseline blood pressure. This is the opposite direction from bremelanotide's transient pressor effect, which means the net blood pressure change from combining the two is not predictable from either effect in isolation.

Because the primary literature search conducted for this article did not return verifiable papers matching the specific numeric effect sizes commonly cited for these mechanisms, this article deliberately avoids stating precise percentages or point estimates. A clinician or pharmacist reviewing an individual case should pull the current primary literature rather than rely on secondary summaries.

Is there a pharmacokinetic interaction?

No mechanism supports one. Bremelanotide's clearance does not depend on CYP enzymes, and omega-3 fatty acids at supplement doses are not established CYP inhibitors or inducers. This is the most confidently stated part of this article: bremelanotide and dietary or supplemental omega-3 fatty acids do not share a metabolic pathway, so a pharmacokinetic drug-supplement interaction is biologically implausible; the residual concern with this combination is pharmacodynamic overlap in platelet function and blood pressure regulation, and it has not been directly tested in a clinical trial.

What is the pharmacodynamic concern, and how strong is it?

This is the part of the picture that requires judgment rather than a lookup answer.

Bremelanotide itself does not have an established direct antiplatelet mechanism. The theoretical concern is additive: a woman on Vyleesi who also takes high-dose omega-3, and who separately uses aspirin, an NSAID, or an anticoagulant, is stacking several agents with some relevance to bleeding risk, even though no two-way pairing among them is formally contraindicated.

On blood pressure, the label's own pivotal-trial data describe a transient rise in blood pressure after each Vyleesi injection, which is why the label instructs checking blood pressure around 12 hours post-dose in women with cardiovascular risk factors, and why cardiovascular or cerebrovascular disease is a listed contraindication. Omega-3's modest blood-pressure-lowering tendency could theoretically blunt that rise in some patients, but nothing in the label or a verified trial has characterized this specific combination, so this remains plausible rather than established.

Evidence-status interaction assessment

What should you actually do?

Most women taking a standard fish oil supplement (roughly 1 to 2 g/day combined EPA/DHA) with no cardiovascular disease, no bleeding disorder, and no other antiplatelet or anticoagulant medication are unlikely to face a clinically meaningful interaction. Standard follow-up for Vyleesi, including blood pressure checks, is reasonable and no additional monitoring is clearly indicated by current evidence.

Women taking 3 g/day or more of omega-3, whether by prescription for hypertriglyceridemia or as a high-dose supplement, should mention this explicitly when starting Vyleesi. A baseline blood pressure check, a check around 12 hours after the first dose, and a bleeding-symptom review at the first follow-up are a reasonable, conservative approach, though this specific protocol is not written into any guideline for this exact combination.

Women with cardiovascular or cerebrovascular disease already have a formal Vyleesi contraindication independent of omega-3 use; in that population, the omega-3 interaction question is secondary to whether Vyleesi is appropriate at all, and that decision belongs with the prescribing clinician.

Women on prescription-dose omega-3 for hypertriglyceridemia or cardiovascular risk reduction should not stop that medication to accommodate Vyleesi without talking to the prescriber who ordered it. The omega-3 was prescribed for a distinct, evidence-based cardiovascular reason, and abrupt discontinuation carries its own trade-offs that a single prescriber may not be positioned to evaluate alone.

Dose-timing separation within the same day is not an established mitigation here. Because the concern is pharmacodynamic (cumulative platelet or vascular tone effects) rather than pharmacokinetic (competition for absorption or metabolism), taking fish oil in the morning and Vyleesi at night does not clearly reduce the theoretical risk the way spacing doses can for a true absorption interaction.

What guidelines say

Professional guidance on HSDD management (from societies such as the International Society for the Study of Women's Sexual Health and the American College of Obstetricians and Gynecologists) emphasizes taking a complete medication and supplement history before starting bremelanotide and being alert to agents that affect hemostasis or blood pressure. This review did not locate a verifiable, quotable guideline statement addressing omega-3 and bremelanotide specifically, and no specific dosing threshold or monitoring protocol for this combination has been published by a professional body as of this writing (2025). Readers should treat any such statement they encounter elsewhere with the same caution, and a prescriber or pharmacist should confirm current guidance directly with the primary source before applying it to an individual patient.

When to seek urgent care

Contact your prescriber promptly, or seek urgent care, if you experience: a blood pressure reading substantially above your usual baseline that does not resolve within about 12 hours of a Vyleesi dose, chest pain, severe headache, unusual or spontaneous bruising, prolonged bleeding from a minor cut, or blood in stool or urine. These are not expected effects of either agent alone at typical doses, and their appearance while combining bremelanotide with omega-3 warrants evaluation rather than self-management.

What this article does not establish

This article does not establish a specific safe upper limit for omega-3 when combined with Vyleesi, a validated monitoring protocol for this exact pairing, or any quantified change in bleeding or cardiovascular event rates from combining the two. No dedicated clinical trial, case series, or pharmacovigilance report specific to this combination was identified during preparation of this draft. Numeric claims that could not be verified against a primary source have been removed or described only in general terms. A qualified prescriber or pharmacist should confirm current FDA labeling and any newer literature before individualizing a decision for a specific patient.

Frequently asked questions